Mast cell mediators in airway remodeling

Chemical Immunology and Allergy

Volumn 87, Issue , 2005, Pages 85-100

  Oh, Chad K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; AUTACOID; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

AIRWAY; ALLERGIC ASTHMA; CELL FUNCTION; CELL INFILTRATION; EXTRACELLULAR MATRIX; FIBROSIS; GENE FREQUENCY; HUMAN; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY SYSTEM; REVIEW; ANIMAL; ASTHMA; CYTOLOGY; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE;

ANIMALS; ASTHMA; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; MAST CELLS; MATRIX METALLOPROTEINASES; MICE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESPIRATORY SYSTEM;

EID: 25144448762     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000087573     Document Type: Review

References (116)

1. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM: Asthma: From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-1745.
2. Jarjour NN, Kelly EA: Pathogenesis of asthma. Med Clin North Am 2002;86:925-936.
3. Chu HW, Halliday JL, Martin RJ, Leung DY, Szefler SJ, Wenzel SE: Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am J Respir Crit Care Med 1998;158:1936-1944.
4. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M: Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003;167:1360-1368.
5. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST: Airway remodeling in asthma: New insights. J Allergy Clin Immunol 2003;111:215-225.
6. Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, Bonsignore G: Airway remodeling in asthma. Chest 2003;123:417S-422S.
7. Jeffery PK: Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:828-838.
8. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992;90:32-42.
9. Vanacker NJ, Palmans E, Kips JC, Pauwels RA: Fluticasone inhibits but does not reverse allergen-induced structural airway changes. Am J Respir Crit Care Med 2000;163:674-679.
10. Collen D: The plasminogen (fibrinolytic) system. Thromb Haemost 1999;82:259-270.
11. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH: Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996;97:232-237.
12. Eddy AA: Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002;283:F209-F220.
13. Oh CK, Ariue B, Alban RF, Shaw B, Cho SH: PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 2002;294:1055-1060.
14. Cho SH, Hall IP, Wheatley A, Dewar J, Abraha D, Del Mundo J, Lee H, Oh CK: Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene in the development of asthma. J Allergy Clin Immunol 2001;108:212-214.
15. Buckova D, Izakovicova Holla L, Vacha J: Polymorphism 4G/5G in the plasminogen activator inhibitor-1 gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy 2002;57:446-448.
16. Global Strategy for Asthma Management and Prevention: NHLBI/WHO Workshop Report, March 1993. Publ No 95-3659. Bethesda, NIH, National Heart, Lung and Blood Institute, 1995.
17. Azzawi M, Bradley B, Jeffery PK, Frew AJ, Wardlaw AJ, Knowles G, Assoufi B, Collins JV, Durham S, Kay AB: Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990;142:1407-1413.
18. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC Jr: Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992;146:109-115.
19. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB: Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298-304.
20. Holgate S: Mediators and cytokine mechanisms in asthma. Thorax 1993;48:103-109.
21. Kay AB: Asthma and inflammation. J Allergy Clin Immunol 1991;87:893-910.
22. Bousquet J, Chanez P, Vignola AM, Lacoste JY, Michel FB: Eosinophilic inflammation in asthma. Am J Respir Crit Care Med 1994;150:S33-S38.
23. Sur S, Adolphson CR, Gleich GJ: Eosinophils: Biochemical and cellular aspects; in Middleton E Jr, Reed CE, Ellis EF (eds): Allergy Principles and Practice, ed 4. St Louis, Mosby, 1993, pp 169-200.
24. Galli SJ, Wershil BK, Costa JJ, Tsai M: For better or for worse: Does stem cell factor importantly regulate mast cell function in pulmonary physiology and pathology? Am J Respir Cell Mol Biol 1994;11:644-645.
25. Williams CM, Galli SJ: Mast cells can amplify airway reactivity and features of chrome inflammation in an asthma model in mice. J Exp Med 2000;192:455-462.
26. Masuda T, Tanaka H, Komai M, Nagao K, Ishizaki M, Kajiwara D, Nagai H: Mast cells play a partial role in allergen-induced subepithelial fibrosis in a murine model of allergic asthma. Clin Exp Allergy 2003;33:705-713.
27. Wasserman SI: Biochemical mediators of allergic reactions; in Patterson R, Grammer LC, Greenberger PA (eds): Allergic Diseases: Diagnosis and Management, ed 5. New York, Lippincott, 1997, pp 49-56.
28. Schwartz LB, Irani AA, Roller K, Castells MC, Schechter NM: Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 1987;138:2611-2615.
29. Longphre M, Zhang LY, Paquette N, Kleeberger SR: PAF-induced airways hyperreactivity is modulated by mast cells in mice. Am J Respir Cell Mol Biol 1996;14:461-469.
30. 2 and 5-lipoxygenase. J Exp Med 1995;182:197-206.
31. Casale TB, Wood D, Richerson HB, Zehr B, Zavala D, Hunninghake GW: Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. J Clin Invest 1987;80:1507-1511.
32. 2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996;98:421-432.
33. Goetzl EJ: Oxygenation products of arachinonic acid as mediators of hypersensitivity and inflammation. Med Clin North Am 1981;65:809-828.
34. 4 synthase. Int Arch Allergy Immunol 1995;107:19-24.
35. Arm JP, Lee TH: Sulphidopeptide leukotrienes in asthma. Clin Sci 1993;84:501-510.
36. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834-846.
37. Holgate ST, Bradding P, Sampson AP: Leukotriene antagonists and synthesis inhibitors: New direction in asthma therapy. J Allergy Clin Immunol 1996;98:1-13.
38. Okada S, Kita H, George TJ, Gleich GJ, Leiferman KM: Transmigration of eosinophils through basement membrane components in vitro: Synergistic effect of PAF and eosinophil active cytokines. Am J Respir Cell Mol Biol 1997;16:455-463.
39. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, Imaizumi T, Takamatsu S, Zimmerman GA, McIntyre TM, Gray PW, Prescott SM: Platelet-activating factor acetylhydrolase deficiency: A missense mutation in the active site of an anti-inflammatory phospholipase. J Clin Invest 1996;97:2784-2791.
40. Hozawa S, Horuta Y, Ishioka S, Yamakido M: Effects of a PAF antagonist Y24180 on bronchial responsiveness in patients with asthma. Am J Respir Crit Care Med 1995;152:1198-1202.
41. Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE: Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or calcium ionophore. Nature 1989;339:64-67.
42. Wodnar-Filipowicz A, Heusser CH, Moroni C: Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature 1989;339:150-152.
43. Burd PR, Rogers HW, Gordon JR, Martin CA, Jayaraman S, Wilson SD, Dvorak AM, Galli SJ, Dorf ME: Interleukin-3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J Exp Med 1989;179:245-257.
44. Gordon JR, Galli SJ: Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature 1990;346:274-276.
45. Malaviya R, Ikeda T, Ross E, Abraham SN: Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 1996;381:77-80.
46. Echtenacher B, Mannel DN, Hultner L: Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996;381:75-77.
47. Gordon JR, Galli SJ: Release of both preformed and newly synthesized tumor necrosis factor-α (TNF-α)/cachectin by mouse mast cells stimulated via the FcRI: A mechanism for the sustained action of mast cell-derived TNF-α during IgE-dependent biological responses. J Exp Med 1991;174:103-107.
48. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST: Interleukin-4, -5, -6 and tumor necrosis factor-α in normal and asthmatic airways: Evidence for the human mast cells as a source of these cytokines. Am J Respir Cell Mol Biol 1994;10:471-480.
49. Moller A, Lippert U, Lessmann D, Kolde G, Hamann K, Welker P, Schadendorf D, Rosenbach T, Luger T, Czarnetzki BM: Human mast cells produce IL-8. J Immunol 1993;151:3261-3266.
50. Nilsson G, Svensson V, Nilsson K: Constitutive and inducible cytokine mRNA expression in the human mast cell line HMC-1. Scand J Immunol 1995;42:76-81.
51. Rumsaeng V, Vliagoftis H, Oh CK, Metcalfe DD: Lymphotactin gene expression in mast cells following Fc(ε) receptor I aggregation: Modulation by TGF-β, IL-4, dexamethasone, and cyclosporin A. J Immunol 1997;158:1353-1360.
52. Oh CK, Metcalfe DD: Transcriptional regulation of the TCA3 gene in mast cells after FcεRI cross-linking. J Immunol 1994;153:325-332.
53. Oh CK, Metcalfe DD: Activated lymphocytes induce promoter activity of the TCA3 gene in mast cells following cell-to-cell contact. Biochem Biophys Res Commun 1996;221:510-514.
54. Oh CK, Neurath M, Cho JJ, Semere T, Metcalfe DD: Two different negative regulatory elements control the transcription of T-cell activation gene 3 in activated mast cells. Biochem J 1997;323:511-519.
55. Gordon JR, Galli SJ: Promotion of mouse fibroblast collagen gene expression by mast cells stimulated via the FcRI: Role for mast cell-derived transforming growth factor and tumor necrosis factor. J Exp Med 1994;180:2027-2037.
56. Sakai K, Ren S, Schwartz LB: A novel heparin-dependent processing pathway for human tryptase. J Clin Invest 1996;97:988-995.
57. Tam EK, Caughey GH: Degradation of neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol 1992;3:27-32.
58. Caughey GH: Mast cell tryptase: Hoisted by its own petard? J Clin Invest 1996;97:895-896.
59. Ruoss SJ, Hartmann T, Caughey GH: Mast cell tryptase is mitogen for cultured fibroblasts. J Clin Invest 1991;88:493-499.
60. Brown JK, Tyler CL, Jones CA, Ruoss SJ, Hartmann T, Caughey GH: Tryptase, the dominant secretory granular protein in human mast cell, is a potent mitogen for cultured dog tracheal smooth muscle cells. Am J Respir Cell Mol Biol 1995;13:227-236.
61. Chetta A, Foresi A, Del Donno M, Consigli GF, Bertorelli G, Pesci A, Barbee RA, Olivieri D: Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma. Am J Respir Crit Care Med 1996;153:910-917.
62. Fang KC, Wolters PJ, Steinhoff M, Bidgol A, Blount JL, Caughey GH: Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-β. J Immunol 1999;162:5528-5535.
63. Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H: Human mast cells produce matrix metalloproteinase 9. Eur J Immunol 1999;29:2645-2649.
64. Frank BT, Rossall JC, Caughey GH, Fang KC: Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by α-chymase. J Immunol 2001;166:2783-2792.
65. Kim HS, Tsai PB, Oh CK: The genetics of asthma. Curr Opin Pulm Med 1998;4:46-48.
66. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-470.
67. Shalon D, Smith S, Brown PO: A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 1996;6:639-645.
68. Cho JJ, Vliagoftis H, Rumsaeng V, Metcalfe DD, Oh CK: Identification and categorization of inducible mast cell genes in a subtraction library. Biochem Biophys Res Commun 1998;242:226-230.
69. Cho SH, Cho JJ, Kim IS, Vliagoftis H, Metcalfe DD, Oh CK: Identification and characterization of the inducible murine mast cell gene, imc-415. Biochem Biophys Res Commun 1998;252:123-127.
70. Cho SH, SW Tam, S Demissie-Sanders, SA Filler, Oh CK: Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol 2000;165:3154-3161.
71. Fowlkes JL, Winkler MK: Exploring the interface between metalloproteinase activity and growth factor and cytokine bioavailability. Cytokine Growth Factor Rev 12002;3:277-287.
72. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
73. Lohi J, Wilson CL, Roby JD, Parks WC: Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem 2001;276:10134-10144.
74. Ye S, Humphries S, Henney A: Matrix metalloproteinases: Implication in vascular matrix remodelling during atherogenesis. Clin Sci 1998;94:103-110.
75. 3. Cell 1996;85:683-693.
76. Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, Yamashita K, Hayakawa T: Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 1992;267:21712-21719.
77. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H: Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 1990;29: 10261-10270.
78. Eeckhout Y, Vaes G: Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J 1977;166:21-31.
79. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989;86:2632-2636.
80. Keski-Oja J, Lohi J, Tuuttila A, Tryggvason K, Vartio T: Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res 1992;202:471-476.
81. Lijnen HR, Silence J, Van Hoef B, Collen D: Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice. Blood 1998;91:2045-2053.
82. Ogata Y, Enghild JJ, Nagase H: Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992;267:3581-3584.
83. Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC, Fuller JA, Toews GB: Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest 1996;97:1818-1826.
84. Shapiro RL, Duquette JG, Roses DF, Nunes I, Harris MN, Kamino H, Wilson EL, Rifkin DB: Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996;56:3597-3604.
85. 2 integrins in vivo. J Exp Med 1998;188:1029-1037.
86. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-928.
87. Cubellis MV, Andreasen P, Ragno P, Mayer M, Dano K, Blasi F: Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci USA 1989;86:4828-4832.
88. Stephens RW, Pollanen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, Ronne E, Behrendt N, Dano K, Vaheri A: Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J Cell Biol 1989;108:1987-1995.
89. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-1571.
90. 3 binding to vitronectin. Nature 1996;383:441-443.
91. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA: Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997;232:420-429.
92. Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE: Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 1998;273:8225-8231.
93. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ: Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor-β. J Biol Chem 1991;266:23048-23052.
94. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993;268:10739-10745.
95. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM: Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091-3100.
96. Van Zonneveld AJ, Curriden SA, Loskutoff DJ: Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci USA 1988;85:5525-5529.
97. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ: Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988;263:5797-5803.
98. Meulders Q, He CJ, Adida C, Peraldi MN, Schleuning WD, Sraer JD, Rondeau E: Tumor necrosis factor-α increases antifibrinolytic activity of cultured human mesangial cells. Kidney Int 1992;42:327-334.
99. Dennler H, Itoh S, Vivien D, Dijke P, Huet S, Gauthier JM: Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091-3100.
100. Arts J, Grimbergen J, Bosma PJ, Rahmsdorf HJ, Kooistra T: Role of c-Jun and proximal phorbol 12-myristate-13-acetate-(PMA)-responsive elements in the regulation of basal and PMA-stimulated plasminogen-activator inhibitor-1 gene expression in HepG2. Eur J Biochem 1996;241:393-402.
101. Bouchie JL, Hansen H, Feener EP: Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 1998;18:1771-1779.
102. Essig M, Vrtovsnik F, Nguyen G, Sraer JD, Friedlander G: Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: Role of geranylgeranylation and Rho proteins. J Am Soc Nephrol 1998;9:1377-1388.
103. Gallicchio M, Hufnagl P, Wojta J, Tipping P: IFN-γ inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J Immunol 1996;157: 2610-2617.
104. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;14;92:1851-1855.
105. Loskutoff DJ, Quigley JP: PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 2000;106:1441-1443.
106. Homer RJ, Elias JA: Consequences of long-term inflammation. Airway remodeling. Clin Chest Med 2000;21:331-343.
107. Stetler-Stevenson WG: Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996;148:1345-1350.
108. Elias JA, Zhu Z, Chupp G, Homer RJ: Airway remodeling in asthma. J Clin Invest 1999;104:1001-1006.
109. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, Chapman HA Jr: Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990;322:890-897.
110. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS: Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989;84:695-705.
111. Bachofen M, Weibel ER: Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis 1977;116:589-615.
112. Chapman HA, Allen CL, Stone OL: Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 1986;133:437-443.
113. Hasday JD, Bachwich PR, Lynch JP 3rd, Sitrin RG: Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. Exp Lung Res 1988;14:261-278.
114. Viscardi RM, Broderick K, Sun CC, Yale-Loehr AJ, Hessamfar A, Taciak V, Burke KC, Koenig KB, Idell S: Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome. Am Rev Respir Dis 1992;146:492-499.
115. Idell S, James KK, Coalson JJ: Fibrinolytic activity in bronchoalveolar lavage of baboons with diffuse alveolar damage: Trends in two forms of lung injury. Crit Care Med 1992;20:1431-1440.
116. Oh CK, Ariue B, Alban RF, Shaw B, Cho SH: PAI-1 promotes extracellular matrix deposition in the airways of amurine asthma model. Biochem Biophys Res Commun 2002;294:1155-1160.